Details

Autor(en) / Beteiligte

• DHEDIN, N
• GIRAUDIER, S
• LAPORTE, J. L
• GUILHOT, F
• KUENTZ, M
• GAULARD, P
• ESPEROU, H
• IFRAH, N
• MICHALLET, M
• MILPIED, N
• RIO, B
• CAHN, J. Y
• MOLINA, L

Titel

Allogeneic bone marrow transplantation in aggressive non‐Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database

Ist Teil von

• British journal of haematology, 1999-10, Vol.107 (1), p.154-161

Ort / Verlag

Oxford, U.K. and Cambridge, USA: Blackwell Science Ltd

Erscheinungsjahr

1999

Quelle

Wiley Online Library Database Model

Beschreibungen/Notizen

• The place of allogeneic bone marrow transplantation (BMT) in the treatment of aggressive non‐Hodgkin's lymphoma (NHL) remains controversial. We conducted a retrospective study of French experience in allografting NHL between 1984 and 1994. To improve the homogeneity of the study population, cases of low‐grade, Burkitt and lymphoblastic NHL were excluded. 73 patients were included in the analysis. Median age at transplantation was 35 years (range 9–61 years); 64 patients were in stage IV and 45 had bone marrow involvement at diagnosis. At the time of transplantation, 46 patients had sensitive disease (25 in complete remission; CR). The overall survival (OS) and progression‐free survival (PFS) rates were 41% and 40% respectively at 5 years (median follow‐up of survivors 90 months). The probability of disease progression was 30% at 5 years, and only one relapse occurred after 15 months. 32 patients died of transplantation‐related complications. In multivariate analysis, pretransplant complete remission was the main factor associated with longer survival (OS at 60 months of 76% among the 25 patients in CR at transplant and of 23% among the 48 patients not in CR at transplant). Neither acute nor chronic graft‐versus‐host disease (GvHD) influenced the relapse rate. In conclusion, in this high‐risk population the overall results of allogeneic BMT were encouraging, despite a high transplant‐related mortality rate. We believe this procedure should be studied further in prospective controlled trials.